FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956109721> ?p ?o ?g. }

• W2956109721 abstract "Intraocular neovascularization is directly related with vascular endothelial growth factor (VEGF) expression. Anti-VEGF agents are the gold standard treatment of retinal and choroidal neovascularization. Curcumin is a natural compound, and it is a promising therapeutic agent to ocular disorders due to anti-oxidative, anti-inflammatory and anti-proliferative properties, previously reported in literature (Beavers & Huang 2011; Aldebasi et al. 2013). Also, it has been reported as a therapeutic agent because of its anti-oxidant, anti-inflammatory and antiangiogenic effect (Mrudula et al. 2007; Beavers & Huang 2011; Zhang et al. 2015). However, few studies of natural compounds with antiangiogenic effect in retinal diseases are available. In this letter, we will discuss the antiangiogenic effect of intravitreal curcumin in different concentrations in an experimental model of retinal neovascularization using VEGF 165 in six male-pigmented rabbits (chinchilla breed) using anterior biomicroscopy, fundus exam, fundus photography, fluorescein angiography (FA), spectral domain optical coherence tomography (SD-OCT) and full-field electroretinography (ERG) at baseline, week 1 and week 2. Retinal neovascularization was confirmed by FA leakage of retina vessels after 1 week. One group received 0.1 mg intravitreal curcumin and the other received 0.3 mg intravitreal curcumin. At week two, rabbits were euthanized and all eyes were sent to histological evaluation after enucleation. The intraocular curcumin injection decreased neovascularization partially with persistent capillary tortuosity in the 0.1 mg curcumin group and complete regression of neovascularization with no persistent capillary tortuosity in the 0.3 mg group (Fig. 1). There was no alteration on SD-OCT and ERG in both groups, and no toxicity was noticed in the histopathology (Fig. 1). Intravitreal injection of curcumin in rabbits caused reduction of retinal neovascularization, especially with 0.3 mg dose of curcumin. However, persistent vascular tortuosity was still present in the animals that received the 0.1 mg of intravitreal curcumin (lower dose). We believe that a higher dose of intravitreal curcumin may be more effective to decrease retinal neovascularization and restore anatomical changes in vasculature. A few studies in literature have shown curcumin antiangiogenic effect such as in corneal neovascularization after 7 days of topical treatment (Pradhan et al. 2015). However, due to a small number of eyes were studied and the short period of time (14 days), further studies must be conducted to confirm these findings. In addition, the specific anti-VEGF mechanism of curcumin is still unclear." @default.
• W2956109721 created "2019-07-12" @default.
• W2956109721 creator A5020276182 @default.
• W2956109721 creator A5037307539 @default.
• W2956109721 creator A5039107268 @default.
• W2956109721 creator A5039172141 @default.
• W2956109721 creator A5047057790 @default.
• W2956109721 creator A5050399571 @default.
• W2956109721 creator A5050995465 @default.
• W2956109721 creator A5080624773 @default.
• W2956109721 creator A5082559631 @default.
• W2956109721 date "2019-07-05" @default.
• W2956109721 modified "2023-10-01" @default.
• W2956109721 title "Antiangiogenic effect of intravitreal curcumin in experimental model of proliferative retinopathy" @default.
• W2956109721 cites W1968879585 @default.
• W2956109721 cites W2016383286 @default.
• W2956109721 doi "https://doi.org/10.1111/aos.14179" @default.
• W2956109721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31273914" @default.
• W2956109721 hasPublicationYear "2019" @default.
• W2956109721 type Work @default.
• W2956109721 sameAs 2956109721 @default.
• W2956109721 citedByCount "3" @default.
• W2956109721 countsByYear W29561097212021 @default.
• W2956109721 countsByYear W29561097212022 @default.
• W2956109721 crossrefType "journal-article" @default.
• W2956109721 hasAuthorship W2956109721A5020276182 @default.
• W2956109721 hasAuthorship W2956109721A5037307539 @default.
• W2956109721 hasAuthorship W2956109721A5039107268 @default.
• W2956109721 hasAuthorship W2956109721A5039172141 @default.
• W2956109721 hasAuthorship W2956109721A5047057790 @default.
• W2956109721 hasAuthorship W2956109721A5050399571 @default.
• W2956109721 hasAuthorship W2956109721A5050995465 @default.
• W2956109721 hasAuthorship W2956109721A5080624773 @default.
• W2956109721 hasAuthorship W2956109721A5082559631 @default.
• W2956109721 hasBestOaLocation W29561097211 @default.
• W2956109721 hasConcept C118487528 @default.
• W2956109721 hasConcept C126322002 @default.
• W2956109721 hasConcept C167734588 @default.
• W2956109721 hasConcept C2776474195 @default.
• W2956109721 hasConcept C2777025900 @default.
• W2956109721 hasConcept C2778250585 @default.
• W2956109721 hasConcept C2778271429 @default.
• W2956109721 hasConcept C2780248432 @default.
• W2956109721 hasConcept C2780394083 @default.
• W2956109721 hasConcept C2780827179 @default.
• W2956109721 hasConcept C2781359195 @default.
• W2956109721 hasConcept C71924100 @default.
• W2956109721 hasConcept C98274493 @default.
• W2956109721 hasConceptScore W2956109721C118487528 @default.
• W2956109721 hasConceptScore W2956109721C126322002 @default.
• W2956109721 hasConceptScore W2956109721C167734588 @default.
• W2956109721 hasConceptScore W2956109721C2776474195 @default.
• W2956109721 hasConceptScore W2956109721C2777025900 @default.
• W2956109721 hasConceptScore W2956109721C2778250585 @default.
• W2956109721 hasConceptScore W2956109721C2778271429 @default.
• W2956109721 hasConceptScore W2956109721C2780248432 @default.
• W2956109721 hasConceptScore W2956109721C2780394083 @default.
• W2956109721 hasConceptScore W2956109721C2780827179 @default.
• W2956109721 hasConceptScore W2956109721C2781359195 @default.
• W2956109721 hasConceptScore W2956109721C71924100 @default.
• W2956109721 hasConceptScore W2956109721C98274493 @default.
• W2956109721 hasFunder F4320312596 @default.
• W2956109721 hasFunder F4320320997 @default.
• W2956109721 hasFunder F4320322025 @default.
• W2956109721 hasIssue "1" @default.
• W2956109721 hasLocation W29561097211 @default.
• W2956109721 hasLocation W29561097212 @default.
• W2956109721 hasOpenAccess W2956109721 @default.
• W2956109721 hasPrimaryLocation W29561097211 @default.
• W2956109721 hasRelatedWork W1964208163 @default.
• W2956109721 hasRelatedWork W2031802632 @default.
• W2956109721 hasRelatedWork W2053648830 @default.
• W2956109721 hasRelatedWork W2074776111 @default.
• W2956109721 hasRelatedWork W2089603816 @default.
• W2956109721 hasRelatedWork W2111383061 @default.
• W2956109721 hasRelatedWork W2211181535 @default.
• W2956109721 hasRelatedWork W2265567290 @default.
• W2956109721 hasRelatedWork W2389303640 @default.
• W2956109721 hasRelatedWork W3031492198 @default.
• W2956109721 hasVolume "98" @default.
• W2956109721 isParatext "false" @default.
• W2956109721 isRetracted "false" @default.
• W2956109721 magId "2956109721" @default.
• W2956109721 workType "article" @default.